T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation

Blood

Volumn 94, Issue 2, 1999, Pages 434-441

  Drobyski, William R ^a   Hessner, Martin J ^b   Klein, John P ^b   Kabler Babbitt, Claudia ^b   Vesole, David H ^b   Keever Taylor, Carolyn A ^b  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOTHERAPY; LEUKOCYTE TRANSFUSION; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0033566306     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.2.434     Document Type: Article

References (41)

1. Mitsuyasu RT, Champlin RE, Gale RP Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J, Terasaki P, Billing R, Feig S: Treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for the prevention of graft-versus-host disease: A prospective, randomized, double-blind trial. Ann Intern Med 105:20,1986
2. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringdén O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991
3. +8 T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76:418, 1990
4. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988
5. Marks DI, Hughes TP, Szydlo R, Kelly S, Cullis JO, Schwarer AP, Mackinnon S, Apperley J, Barrett AJ, Hows JM, Goldman JM: HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol 81:383, 1992
6. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995
7. Drobyski W, Keever C, Roth M, Koethe S, Hanson G, McFadden P, Gottschall J, Ash R, Van Tuinen P, Horowitz M, Flomenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310, 1993
8. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433, 1997
9. Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M, Heinze B, Hubner G, Heimpel H, Arnold R: Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 56:1114, 1993
10. Bar BMAM, Schattenberg A, Mensink EJBM, Van Kessel G, Smetsers TFCM, Knops GHJN, Linders EHP, De Witte T: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 11:513, 1993
11. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent CML after BMT Bone Marrow Transplant 12:125, 1993
12. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host diseases immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994
13. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T, Flomenberg N: Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 83:1980, 1994
14. Baxter-Lowe LA, Eckels DD, Ash R, Casper J, Hunter JB, Gorski J: The predictive value of HLA-DR oligotyping for MLC responses. Transplantation 53:1352, 1992
15. Molkentin J, Gorski J, Baxter-Lowe LA: Detection of 14 HLA-DQB1-alleles by oligotyping. Hum Immunol 31:114, 1991
16. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA, Gottschall JL, Oldham K, Anderson T, Camitta B, Menitove J: Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 322:485, 1990
17. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR: Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 86:3987, 1995
18. Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S: T10B9. 1A-31 anti-T-cell monoclonal antibody: Preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis 14:61, 1989
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295, 1974
20. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MJ, Storb R, Thomas ED: Chronic graft-versus-host syndrome in man: A long term clinicopathologic study of 20 Seattle patients. Am J Med 69:204, 1980
21. Link CJ, Burt RK, Traynor AE, Drobyski WR: Adoptive immunotherapy for leukemia: Donor lymphocytes transduced with the herpes thymidine kinase gene for remission induction. Hum Gene Ther 9:115, 1998
22. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995
23. Lind F, Goldman JM, Cross NC: A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukemia. Br J Haematol 86:683, 1994
24. Hessner MJ, Roth MS, Drobyski WR, Baxter-Lower LA: Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Genet Anal Tech Appl 11:90, 1994
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
26. Pepe MS, Motomi M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12:737, 1993
27. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer-Verlag, 1997
28. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WE, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greensberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Storb R, Sullivan K, Weiden PL, Witherspoon R: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155, 1986
29. Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954, 1993
30. Van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, de Witte T, Kolb HJ, Niederwiser D, Jacobsen N, Gahrton G, Bandini G, Carreras E, Bacigalupo A, Michallet M, Ruutu T, Reiffers J, Goldman JM, Apperley J, Gratwohl A: Long term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:553, 1997
31. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
32. Schattenberg A, Preijers F, Mensink E, Bar B, Schaap N, Geurts van Kessel A, van der Maazen R, de Witte T: Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome positive CML in first chronic phase. Bone Marrow Transplant 19:1205, 1997
33. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C, Reiter E, Niederwieser D, Hoecker P, Greinix HT: Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia. Blood 89:3113, 1997
34. Bonini Ch, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719, 1997
35. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337, 1995
36. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671, 1998
37. Cullis JO, Marks DI, Schwarer AJ, Hows JM, Swirsky DM, Goldman JM: Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukemia: A report of five cases. Br J Haematol 81:378, 1992
38. Hughes TP, Economou K, Mackinnon S, Vlitos M, Arthur CK, Guo AP, Rassool F, Apperley JF, Hows J, Goldman JM: Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. Br J Haematol 73:462, 1989
39. Porter DL, Collins R, Drobyski W, Connors JM, van Hoef M, Antin J: Long term follow-up of 55 patients who achieved complete remission after donor leukocyte infusions for relapse after allogeneic bone marrow transplantation. Blood 90:549a, 1997 (abstr, suppl 1)
40. Van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377, 1994
41. Raanani P, Dazzi F, Sohal J, Szydlo RM, van Rhee F, Reiter A, Lin F, Goldman JM, Cross NCP: The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 99:945, 1997